| Sara Jamie Reinganum, MD | |
|
13847 East 14th Street, Suite 109, San Leandro, CA 94578-2625 | |
| (510) 357-7141 | |
| (510) 357-4274 |
| Full Name | Sara Jamie Reinganum |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 35 Years |
| Location | 13847 East 14th Street, San Leandro, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083647523 | NPI | - | NPPES |
| 00G706420 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | G70642 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eden Medical Center | Castro valley, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Epic Care | 5890053094 | 45 |
News Archive
Huntington's disease is caused by a mutation in the Huntington's disease gene, but it has long been a mystery why some people with the exact same mutation get the disease more severely and earlier than others. A closer look at the DNA around the Huntington's disease (HD) gene offers researchers a new understanding of how the gene is controlled and how this affects the disease.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval for the treatment of symptomatic Vitreomacular Adhesion.
More than 300,000 women from across the U.S. have signed up for the Love/Avon Army of Women creating a nationwide movement to eradicate breast cancer. Eighty percent of the women who have joined the Army of Women have never had breast cancer, but want to play a role in ending the disease once and for all.
A study led by the University of Kentucky researcher Elaine Wittenberg-Lyles found that hospice family caregivers are "second order patients" themselves and require their own unique care needs.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
› Verified 6 days ago
| Entity Name | Epic Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780107797 PECOS PAC ID: 5890053094 Enrollment ID: O20171215002809 |
News Archive
Huntington's disease is caused by a mutation in the Huntington's disease gene, but it has long been a mystery why some people with the exact same mutation get the disease more severely and earlier than others. A closer look at the DNA around the Huntington's disease (HD) gene offers researchers a new understanding of how the gene is controlled and how this affects the disease.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval for the treatment of symptomatic Vitreomacular Adhesion.
More than 300,000 women from across the U.S. have signed up for the Love/Avon Army of Women creating a nationwide movement to eradicate breast cancer. Eighty percent of the women who have joined the Army of Women have never had breast cancer, but want to play a role in ending the disease once and for all.
A study led by the University of Kentucky researcher Elaine Wittenberg-Lyles found that hospice family caregivers are "second order patients" themselves and require their own unique care needs.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sara Jamie Reinganum, MD 13847 East 14th Street, Suite 109, San Leandro, CA 94578-2625 Ph: (510) 357-7141 | Sara Jamie Reinganum, MD 13847 East 14th Street, Suite 109, San Leandro, CA 94578-2625 Ph: (510) 357-7141 |
News Archive
Huntington's disease is caused by a mutation in the Huntington's disease gene, but it has long been a mystery why some people with the exact same mutation get the disease more severely and earlier than others. A closer look at the DNA around the Huntington's disease (HD) gene offers researchers a new understanding of how the gene is controlled and how this affects the disease.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval for the treatment of symptomatic Vitreomacular Adhesion.
More than 300,000 women from across the U.S. have signed up for the Love/Avon Army of Women creating a nationwide movement to eradicate breast cancer. Eighty percent of the women who have joined the Army of Women have never had breast cancer, but want to play a role in ending the disease once and for all.
A study led by the University of Kentucky researcher Elaine Wittenberg-Lyles found that hospice family caregivers are "second order patients" themselves and require their own unique care needs.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
› Verified 6 days ago
Dr. Lamont D Paxton, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 13851 E 14th St, Suite 202, San Leandro, CA 94578 Phone: 510-347-4700 Fax: 510-347-4712 | |
Mr. Daniel Bradley Allen, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 13847 East 14th Street, Suite 109, San Leandro, CA 94578 Phone: 510-357-7141 Fax: 510-357-4274 | |
Donato Joseph Stinghen, MD Surgery Medicare: May Accept Medicare Assignments Practice Location: 13851 E 14th St Ste 202, San Leandro, CA 94578 Phone: 510-347-4700 Fax: 510-347-4712 | |
Brian Walker, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 13847 E 14th St, Suite 118, San Leandro, CA 94578 Phone: 510-352-8400 | |
Kian Mostafavi, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-1000 Fax: 937-208-4286 | |
Dr. Robert O. Gingery, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 13851 E 14th St, Suite 202, San Leandro, CA 94578 Phone: 510-347-4700 Fax: 510-347-4712 |